Skip to main content

Principles of Fistula Repair

Fistula repair requires control of infection, definition of anatomy, optimization and a reconstruction appropriate to the tissue and organs involved. Urinary, bowel and vascular-urinary fistulae differ substantially: an enterocutaneous fistula nutrition protocol or a VVF closure technique should not be applied to every fistula. Vascular-urinary bleeding may require emergency vascular control before reconstructive planning.[1][2][3][4]

Why Fistulae Persist​

Understanding why fistulae fail to close spontaneously is the foundation of all management. Four classical mechanisms prevent spontaneous healing:[5]

  1. Distal obstruction maintaining flow through the tract
  2. Foreign body or calculus physically blocking closure (suture material, ureteral stent, mesh)
  3. Granulomatous tissue or malignancy in the tract (TB, Crohn's disease, cancer)
  4. Epithelialization of the tract — the fistula develops its own lining and becomes self-sustaining

A fifth, increasingly recognized in pelvic reconstruction, is radiation-induced tissue ischemia — irradiated tissue has poor vascularity and impaired healing capacity.[6][7]

The mnemonic FRIEND captures the same ideas for enterocutaneous fistulae and provides a useful checklist for some urinary fistulae: Foreign body, Radiation, Infection / inflammation, Epithelialization, Neoplasm, Distal obstruction.[3][8]

Phased Management​

Recognition, resuscitation and source control​

Treat sepsis, drain collections, relieve obstruction and replace fluid/electrolyte losses when present. Use antimicrobials for infection, with cultures and source control guiding treatment. Skin protection and controlled effluent collection are particularly important for external bowel fistulae. Urinary drainage may use a bladder catheter, ureteral stent or nephrostomy according to the level of the leak.[1][2][11]

The often-quoted 68% figure is from a 1978 external gastrointestinal fistula cohort: that proportion of deaths occurred with uncontrolled sepsis. It is not a mortality estimate for uncomplicated VVF. Likewise, the high-output threshold of 500 mL/day is used in enterocutaneous fistula care, not as a universal urinary-fistula classification.[3][9]

Define anatomy and optimize​

Select imaging and endoscopy to establish the involved organs, obstruction, collections and tissue condition. Assess nutrition and functional reserve individually. Patients with enterocutaneous fistulae can have substantial protein, fluid and electrolyte losses; specialist nutrition support may include enteral feeding, fistuloclysis or parenteral nutrition according to anatomy and tolerance. Malnutrition is not nearly universal in all GU fistula populations.[2][3][4][10]

Low albumin was associated with mortality in a postoperative enterocutaneous fistula cohort, but a threshold of 3.0 g/dL is not a nutritional diagnosis or a stand-alone clearance target for repair.[13]

Reassess the need for definitive treatment​

Persistence despite drainage and correction of reversible factors prompts a reconstructive assessment. There is no universal requirement to operate at 4–6 weeks. Particularly after an open abdomen or enteroatmospheric fistula, definitive reconstruction may need to wait until recovery and wound healing. Timing depends on tissue condition, sepsis, anatomy and the patient's goals.[10][24][31]

Factors Predicting Spontaneous Closure​

Foreign material, distal obstruction, active infection/inflammation, malignancy, radiation injury and an epithelialized tract can make spontaneous healing less likely.[5][8][14] Prediction is anatomy-specific:

  • Enterocutaneous fistulae: high output, jejunal origin, multiple tracts and sepsis were adverse factors in a 174-patient postoperative cohort. Tract length and intestinal continuity also matter; these findings do not establish urinary-fistula cutoffs.[9][13]
  • VVF: a recent, small defect with viable tissue may merit a trial of bladder drainage; closure is uncommon overall and the evidence is mainly retrospective.[27]
  • Ureterovaginal fistula: early stenting can succeed in selected cases. A 17-study retrospective meta-analysis reported 32% pooled success overall, with substantially different results by timing; this is not evidence that 42% of vesical fistulae close conservatively.[18]

Approach Selection​

Choose the exposure that permits safe access, ureteral protection and a tension-free repair. For VVF, vaginal accessibility and associated reconstruction matter more than a simple low/high label; selected high fistulae are accessible vaginally. An abdominal approach may be needed for inaccessible defects or ureteral reimplantation.[17][27]

Use the separate female, male and all-patient atlases for anatomy-specific options. Extensive tissue loss, irradiation, associated outlet disease and prior repairs may require vascularized tissue, staged reconstruction or diversion. A procedure ranking from a selected case series is not a universal algorithm.[1][2]

Timing​

Older practice often delayed urinary-fistula repair for several months to let inflammation settle. Current EAU guidance individualizes timing once edema, inflammation, necrosis and infection have resolved; no fixed waiting period fits all patients.[15][27]

Recent observational reports support feasibility of selected early repairs, not equivalence or a causal benefit of earlier surgery:

  • Adinata's 2026 retrospective series of 80 women defined early transvaginal VVF repair as less than four weeks, not less than three months. Its higher early-group success was not a randomized noninferiority comparison.[16]
  • Zhang's 2026 mixed GU-fistula cohort associated longer delay with failure; confounding by complexity and referral history prevents concluding that delay itself caused failure.[6]
  • The ureterovaginal meta-analysis found 95% pooled success for stenting within two weeks versus 20% after six weeks, but every included study was retrospective. Prompt recognition and drainage are reasonable; the figures are not a guarantee for an individual patient.[18]

Tension-free Closure and Tissue Preservation​

Aim for viable tissue, adequate mobilization, secure closure and appropriate drainage. For bladder repairs, test watertightness without overdistending the reconstruction. Separate adjacent organ repairs and offset suture lines where feasible.[1][27]

There is no rule that every successful fistula repair must have the same number of layers. The 2026 Cochrane publication is a review protocol, not a completed comparative review; its background describes one- or two-layer bladder closure. It cannot establish superiority of a particular operative method.[19]

Remove foreign material and nonviable tissue, while preserving tissue needed for closure. Wide tract excision is not mandatory for every VVF: Latzko repair closes selected apical defects without formal tract excision, and EAU's review of a trimming trial did not establish better closure from trimming.[19][27]

For enterocutaneous fistula surgery, a 205-patient retrospective series found more recurrence after oversewing/wedge repair than resection and reanastomosis (36% versus 16%). This supports resection when feasible in that setting, rather than a universal rule for urinary fistulae.[11]

Tissue Interposition​

Vascularized tissue can separate closures and supplement a compromised bed. Consider it for selected recurrent, irradiated or tissue-deficient repairs; it does not guarantee closure. Evidence for routine interposition in simple VVF is limited, and success rates from different flap series cannot rank the flaps.[7][27]

TissueCommon usePlanning considerations
Martius fat padVaginal or urethral repairsReach, pedicle integrity, labial wound and sensory effects
OmentumAbdominal or combined pelvic repairsAvailable length, prior operations and abdominal morbidity
GracilisComplex perineal or rectourinary repairsVascular supply, reach and donor morbidity
PeritoneumSelected abdominal VVF repairsLocal tissue quality and a tension-free pedicle

Technique-specific pages give the relevant cohorts and limitations. ASCRS recommends Martius or gracilis for selected complex/recurrent RVF; it does not mandate trying them in a fixed sequence.[20][21]

Diversion and Stenting​

Provide reliable low-pressure drainage suited to the repair. Nephrostomy is an appropriate planned option for upper-tract leakage or failed retrograde drainage, not merely an intervention of last resort.[1][18]

Postoperative bladder-catheter duration is not universally 2–4 weeks:

  • WHO: 7–10 days after selected simple obstetric urinary fistula repairs.[28]
  • IUGA/ICS 2026 obstetric consensus: experts favored at least 10–14 days, while recognizing WHO's shorter-duration evidence.[29]
  • EAU: expert opinion suggests 10–14 days for simple/postsurgical VVF and 14–21 days for complex or postradiation repair.[27]

Use the operative findings, drainage function and assessment for persistent leakage to plan removal. These recommendations concern different case mixes and are not proof that every longer or shorter regimen is equivalent. Fecal diversion is individualized for RVF/RUF; it has not improved closure in every comparative series.[21]

Pharmacologic Adjuncts — Somatostatin and Octreotide​

Somatostatin analogues have been studied to reduce gastrointestinal fistula secretions. Older reviews and ASPEN-FELANPE guidance were more favorable about closure, but they should be read alongside the updated evidence.[3][22][23]

A 2025 meta-analysis of nine randomized trials (442 participants) found no significant increase in closure (seven trials, RR 1.11, 95% CI 0.95–1.28). Time to closure was about six days shorter; mortality, complications and need for surgery did not differ significantly. Regimens and fistula types varied, and certainty was mostly low. This supports a selective output-management adjunct, not a proven closure treatment or a urinary-fistula therapy.[30]

Negative Pressure Wound Therapy (NPWT / VAC)​

For an open abdominal wound with an enteroatmospheric fistula, the immediate goals are effluent isolation, protection of exposed bowel and wound healing. NPWT can help achieve those goals, but should not be applied directly to exposed viscera. Definitive fistula reconstruction is usually delayed until recovery and wound healing.[31]

An older 151-patient review comprised only level-IV studies; its median 64.6% closure rate is not a controlled estimate of benefit. In a later 77-patient enteroatmospheric series, 14 healed without surgery and 56 required intestinal reconstruction. Do not promise spontaneous tract closure from granulation or extrapolate this evidence to routine urinary fistula care.[12][24]

Radiation-Bed Considerations​

Radiated tissue is non-compliant, hypovascular, and slow to heal. Radiation-associated fistula planning includes:

  • Consider vascularized interposition with suitable non-irradiated tissue when repair is feasible; some patients need diversion instead.[7][27]
  • Staged reconstruction in which the first step is optimization rather than closure.
  • Honest pre-op counseling that failure rates are higher and that permanent dual diversion is a legitimate reconstructive answer — not a failure — for the most hostile cases.
  • A 67-patient, mixed urogenital fistula series reported 75% failure in its irradiated subgroup versus 10.8% without irradiation; subgroup size and referral case mix limit generalization.[6]

The Failed Repair​

Every failed repair is a teaching case. The sequence is:

  1. Confirm the diagnosis.
  2. Image the tract.
  3. Reassess the tissue bed.
  4. Decide whether the next operation adds what the previous one lacked — better approach, vascularized flap, protective diversion, or simply more time.
  5. Obtain patient agreement that further attempts are reasonable.

Escalating to permanent dual diversion is sometimes the correct next step rather than another attempt at closure.

Interpreting Outcomes​

Report anatomical closure, continence, complications, quality of life and reoperation separately. Always identify the fistula type, etiology, prior repairs, denominator and follow-up.[29]

  • Zhang's 67-patient mixed GU-fistula cohort reported 80.6% success after first repair and 92.5% ultimately; VVF success was 89.7%. The overall final rate is not a VVF-only estimate.[6]
  • Singh's 638-patient mixed GU cohort reported first-repair success of 93.95%, 94.24% and 96.55% in selected abdominal, vaginal and laparoscopic groups. These retrospective groups do not prove route superiority.[25]
  • Historical external gastrointestinal/enterocutaneous cohorts reported spontaneous closure around 32–37% and substantial sepsis-related morbidity. Those rates should not be quoted as urinary-fistula outcomes.[9][13]
  • In Crohn-related anorectal fistulae, treatment combines control of sepsis and luminal/perianal inflammation with appropriate medical and surgical therapy. Drain an abscess before relying on immune-directed treatment or definitive closure.[21][26]

Practical Checklist​

PrincipleApplication
Control infection and lossesDrain collections, treat infection, relieve obstruction and replace losses appropriate to the fistula.
Assess nutrition and reserveIndividualize support; do not use an albumin target or an ECF feeding prescription for every GU fistula.
Define anatomyEstablish involved organs, tissue condition, obstruction and associated disease.
Preserve viable tissueRemove foreign material and nonviable tissue; avoid unnecessary tissue sacrifice.
Plan exposure and closureAim for a tension-free repair with secure organ closure; layers and interposition depend on anatomy.
Plan drainage and follow-upSpecify catheter/stent function, duration, assessment before removal and the patient's functional goals.
Individualize timingUse recovery, tissue condition and the consequences of waiting, rather than a universal calendar interval.

These principles require the anatomy-specific guidance and evidence limitations described above.[1][3][21][27][29]

See Also​

References​

1. Wei N, Pfeuti C, Linder BJ. "Contemporary Genitourinary Fistula Management: Treatment, Trends, and Innovations." Curr Opin Obstet Gynecol. 2025. doi:10.1097/GCO.0000000000001065

2. Mellano EM, Tarnay CM. "Management of Genitourinary Fistula." Curr Opin Obstet Gynecol. 2014;26(5):415–423. doi:10.1097/GCO.0000000000000095

3. Kumpf VJ, de Aguilar-Nascimento JE, Diaz-Pizarro Graf JI, et al. "ASPEN-FELANPE Clinical Guidelines: Nutrition Support of Adult Patients With Enterocutaneous Fistula." JPEN J Parenter Enteral Nutr. 2017;41(1):104–112. doi:10.1177/0148607116680792

4. Polk TM, Schwab CW. "Metabolic and Nutritional Support of the Enterocutaneous Fistula Patient: A Three-Phase Approach." World J Surg. 2012;36(3):524–533. doi:10.1007/s00268-011-1315-0

5. Jones J, Aboumarzouk OM. "Fistulae and Sinuses." Chapter 24.

6. Zhang C, Saussine C, Tricard T. "Urogenital Fistulas: Surgical Management, Outcomes, and Prognostic Factors: A 14-Year Monocentric Experience." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06580-0

7. Kapriniotis K, Loufopoulos I, Gresty HCM, Greenwell TJ, Ockrim JL. "The Utility of Martius Fat Pad in the Repair of Urogenital Fistulae: Review of Current Evidence." BJU Int. 2024;134(3):365–374. doi:10.1111/bju.16350

8. Pfeifer J, Tomasch G, Uranues S. "The Surgical Anatomy and Etiology of Gastrointestinal Fistulas." Eur J Trauma Emerg Surg. 2011;37(3):209–213. doi:10.1007/s00068-011-0104-7

9. Reber HA, Roberts C, Way LW, Dunphy JE. "Management of External Gastrointestinal Fistulas." Ann Surg. 1978;188(4):460–467. doi:10.1097/00000658-197810000-00003

10. Lloyd DA, Gabe SM, Windsor AC. "Nutrition and Management of Enterocutaneous Fistula." Br J Surg. 2006;93(9):1045–1055. doi:10.1002/bjs.5396

11. Lynch AC, Delaney CP, Senagore AJ, et al. "Clinical Outcome and Factors Predictive of Recurrence After Enterocutaneous Fistula Surgery." Ann Surg. 2004;240(5):825–831. doi:10.1097/01.sla.0000143895.17811.e3

12. Misky A, Hotouras A, Ribas Y, Ramar S, Bhan C. "A Systematic Literature Review on the Use of Vacuum Assisted Closure for Enterocutaneous Fistula." Colorectal Dis. 2016;18(9):846–851. doi:10.1111/codi.13351

13. Martinez JL, Luque-de-Leon E, Mier J, Blanco-Benavides R, Robledo F. "Systematic Management of Postoperative Enterocutaneous Fistulas: Factors Related to Outcomes." World J Surg. 2008;32(3):436–443. doi:10.1007/s00268-007-9304-z

14. Lunniss PJ, Sheffield JP, Talbot IC, Thomson JP, Phillips RK. "Persistence of Idiopathic Anal Fistula May Be Related to Epithelialization." Br J Surg. 1995;82(1):32–33. doi:10.1002/bjs.1800820112

15. Lee RA, Symmonds RE, Williams TJ. "Current Status of Genitourinary Fistula." Obstet Gynecol. 1988;72(3 Pt 1):313–319.

16. Adinata Y, Hudaya S, Hutasoit YI, et al. "Prognostic Factors of Transvaginal Repair for Vesicovaginal Fistulas: A 5-Year Single-Center Study." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06561-3

17. Wang Y, Hadley HR. "Nondelayed Transvaginal Repair of High Lying Vesicovaginal Fistula." J Urol. 1990;144(1):34–36. doi:10.1016/s0022-5347(17)39359-x

18. Bahuguna G, Panwar VK, Mittal A, et al. "Management Strategies and Outcome of Ureterovaginal Fistulae: A Systematic Review and Meta-Analysis." Neurourol Urodyn. 2022;41(2):562–572. doi:10.1002/nau.24874

19. Okada Y, Matsushita T, Hasegawa T, et al. "Surgical Interventions for Treating Vesicovaginal Fistula in Women." Cochrane Database Syst Rev. 2026;1:CD015413. Protocol. doi:10.1002/14651858.CD015413

20. de Bruijn H, Maeda Y, Murphy J, Warusavitarne J, Vaizey CJ. "Combined Laparoscopic and Perineal Approach to Omental Interposition Repair of Complex Rectovaginal Fistula." Dis Colon Rectum. 2018;61(1):140–143. doi:10.1097/DCR.0000000000000980

21. Gaertner WB, Burgess PL, Davids JS, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula." Dis Colon Rectum. 2022;65(8):964–985. doi:10.1097/DCR.0000000000002473

22. Rahbour G, Siddiqui MR, Ullah MR, et al. "A Meta-Analysis of Outcomes Following Use of Somatostatin and Its Analogues for the Management of Enterocutaneous Fistulas." Ann Surg. 2012;256(6):946–954. doi:10.1097/SLA.0b013e318260aa26

23. Coughlin S, Roth L, Lurati G, Faulhaber M. "Somatostatin Analogues for the Treatment of Enterocutaneous Fistulas: A Systematic Review and Meta-Analysis." World J Surg. 2012;36(5):1016–1029. doi:10.1007/s00268-012-1494-3

24. Wainstein DE, Calvi RJ, Rezzonico F, et al. "Management of Enteroatmospheric Fistula: A Ten-Year Experience Following Fifteen Years of Learning." Surgery. 2023;173(4):1079–1085. doi:10.1016/j.surg.2022.12.001

25. Singh V, Bhandari K, Mandal S, et al. "Evolving Surgical Strategies for Management of Genitourinary Fistula Repair Over 25 Years: Insights From a Paradigm Shift." Int J Gynaecol Obstet. 2026;173(1):283–295. doi:10.1002/ijgo.70598

26. Scharl M, Rogler G, Biedermann L. "Fistulizing Crohn's Disease." Clin Transl Gastroenterol. 2017;8(7):e106. doi:10.1038/ctg.2017.33

27. European Association of Urology. Non-neurogenic Female LUTS guideline, section 4.8: urinary fistula. 2026 edition. Full guideline section.

28. World Health Organization. WHO recommendation on duration of bladder catheterization after surgical repair of simple obstetric urinary fistula. 2018. Official recommendation summary.

29. Maljaars LP, Corcos J, Ghoniem G, et al. Consensus statements on the definition of surgical success following obstetric urinary pelvic floor fistula repair: an IUGA-ICS proposal. Int Urogynecol J. 2026. Original consensus paper.

30. Ribeiro Junior MAF, Vieira LF, Thalib HI, et al. Somatostatin-based therapies for external gastrointestinal fistulas: updated meta-analysis of randomized clinical trials. World J Gastrointest Pharmacol Ther. 2025;16(4):111889. doi:10.4292/wjgpt.v16.i4.111889.

31. Coccolini F, Roberts D, Ansaloni L, et al. The open abdomen in trauma and non-trauma patients: WSES guidelines. World J Emerg Surg. 2018;13:7. doi:10.1186/s13017-018-0167-4.